Stockscreener 앱 받기
823.62
3.72%
29.52
시장 영업 전:
819.75
-3.87
-0.47%
전일 마감가:
$794.10
열려 있는:
$825.115
하루 거래량:
6.06M
Relative Volume:
1.67
시가총액:
$713.24B
수익:
$49.00B
순이익/손실:
$11.11B
주가수익비율:
67.02
EPS:
12.29
순현금흐름:
$-1.27B
1주 성능:
-6.89%
1개월 성능:
+0.66%
6개월 성능:
+0.57%
1년 성능:
+8.96%
1일 변동 폭
$807.59
$831.53
1주일 범위
$792.07
$902.50
52주 변동 폭
$677.09
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
823.62 | 713.24B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.12 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
198.47 | 329.14B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.23 | 275.58B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
114.29 | 221.49B | 53.22B | 12.86B | 14.85B | 6.39 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
3 No-Brainer Stocks to Buy in May - The Motley Fool
Eli Lilly’s Strategic Adjustments and Growth Prospects Reinforce Buy Rating Despite Setbacks - TipRanks
Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
This pill could forever change how people lose weight3 May 2025Time Magazine EuropeReadly | All magazines - Readly | All magazines - one magazine app subscription
Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript - Insider Monkey
Eli Lilly (LLY) Stock Rating Maintained by UBS Despite Price Tar - GuruFocus
Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance - Yahoo Finance
UBS cuts Eli Lilly stock target to $1,050, maintains Buy rating - Investing.com UK
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - AOL.com
Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why. - MSN
Cantor Fitzgerald maintains $975 target on Eli Lilly stock By Investing.com - Investing.com India
Cantor Fitzgerald maintains $975 target on Eli Lilly stock - Investing.com
Eli Lilly Stays Strong Despite CVS Dropping Key Drug - Finimize
Leerink sees Eli Lilly stock dip as buying chance, keeps $944 target - Investing.com India
Lilly to participate in Bank of America Securities 2025 Healthcare Conference - Quantisnow
Eli Lilly CFO to Share Strategic Insights at Major Bank of America Healthcare Conference - Stock Titan
Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges - TipRanks
Eli Lilly (LLY) Price Target Reduced by UBS Analyst Despite Stro - GuruFocus
Eli Lilly (LLY) sell-off 'overdone' on CVS move on WegovyLeerink - StreetInsider
Eli Lilly Tackles CVS Health's Cut In Zepbound Coverage - Finimize
Street View: Eli Lilly well positioned in weight-loss market despite CVS's decision - TradingView
Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan - TipRanks
Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures - TipRanks
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight - GuruFocus
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus
Eli Lilly (LLY) Faces Market Cap Drop Amid Competitive Pressure - GuruFocus
Eli Lilly (LLY) Prepares for Potential Tariffs on Pharmaceuticals - GuruFocus
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal - MSN
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Reuters
Friday Five – Pharma's tariff-proofing playbook, Novo slims Lilly's lead, vaccine policy shakeup…and more - FirstWord Pharma
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly - Bloomberg.com
Lilly Cuts Earnings Guidance on Research Charges, Shares Fall - Bloomberg.com
Eli Lilly (LLY) Stock: Shares Tumble 10% Despite 45% Revenue Surge in Q1 2025 - CoinCentral
Eli Lilly and Company (LLY) Stock Price, News, Quote & History - Yahoo Finance
CVS Drops Lilly’s Zepbound from Preferred Coverage in Novo Win - Bloomberg.com
Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates - Yahoo
Eli Lilly (LLY) Gains WHO Support for Obesity Drug Zepbound - GuruFocus
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge By Reuters - Investing.com
Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years? - Insider Monkey
Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade' - Yahoo Finance
Why Eli Lilly (LLY) Stock Is Nosediving - Yahoo Finance
Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday By Investing.com - Investing.com Nigeria
Eli Lilly Earnings: Solid Performance Overshadowed by Novo’s Obesity Coverage Win - Morningstar
Eli Lilly (NYSE:LLY) Reports Strong Q1 Growth Despite Lowered 2025 EPS Guidance - Yahoo Finance
Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday - Investing.com
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone - Seeking Alpha
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy - Yahoo Finance
Eli Lilly's earnings beat is clouded by Novo news. What it means for investors - CNBC
Why Eli Lilly Stock Is Sinking Today - MSN
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.07%
0.10%
자본화:
|
볼륨(24시간):